2024-511593-70-00招募中3 期
Multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of filgotinib in children and adolescents from 8 years to less than 18 years of age with polyarticular-course juvenile idiopathic arthritis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 57
- 试验地点
- 52
- 主要终点
- Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuation (up to approximately Week 22 or throughout the duration of the study)
研究概览
简要总结
The main aim of the study is to evaluate the safety, tolerability, PK, and efficacy of filgotinib in subjects with pJIA.
入排标准
- 年龄范围
- 0 years 至 17 years（0-17 Years）
- 接受健康志愿者
- 否
入选标准
- •Subject and/or parent/legal guardian must be able and willing to comply with the clinical study protocol requirements and must sign and date the ICF and assent (if required per local regulation) as approved by the Independent Ethics Committee / Institutional Review Board, prior to any screening evaluations.
- •Female or male subject 8 to <18 years of age, on the date of signing the informed consent and assent (per local regulation).
- •Subject must meet the ILAR classification and have moderately to severely active disease for one of the following categories that is not adequately controlled with his/her current therapy (see Protocol Appendix 1 for disease activity assessment criteria): • Extended oligoarthritis (i.e. affecting a total of more than 4 joints after the first 6 months of disease) • RF-positive polyarthritis • RF-negative polyarthritis • PsA • ERA
- •Subject with intolerance or a history of inadequate response to at least one of the following medications for the treatment of pJIA, administered for at least 3 months, based on current treatment guidelines: conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs; including methotrexate) and/or biologic disease modifying anti-rheumatic drugs (bDMARDS) administered per local label, and/or non-steroidal anti-inflammatory drugs for ERA and PsA subtypes.
- •Female subject of childbearing potential who is sexually active and at risk for pregnancy must agree to use contraception/preventive exposure measures as described in the protocol.
排除标准
- •Subject with a body weight <15 kg.
- •Subject with persistent oligoarthritis (i.e. affecting not more than 4 joints throughout the disease course).
- •Subject with undifferentiated arthritis.
- •Subject with anterior uveitis (active or uncontrolled) ≤12 weeks prior to baseline.
- •Subject with systemic JIA.
- •Subject with any other rheumatic disease, inflammatory, or immunologic disease (e.g. inflammatory bowel disease, hypogammaglobulinemia, or systemic lupus erythematosus).
- •Subject has any condition or circumstances (including abnormalities in laboratory parameters) that, in the opinion of the investigator, may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.
- •Subject has an active infection.
- •Subject with a history of complicated herpes zoster infection (with multi-dermatomal, disseminated, ophthalmic, or central nervous system involvement).
研究组 & 干预措施
GLPG0634
Test
干预措施: GLPG0634 (Drug)
Jyseleca 200 mg film-coated tablets, Jyseleca 100 mg film-coated tablets
Test
干预措施: Jyseleca 200 mg film-coated tablets (Drug)
Jyseleca 200 mg film-coated tablets, Jyseleca 100 mg film-coated tablets
Test
干预措施: Jyseleca 100 mg film-coated tablets (Drug)
结局指标
主要结局
Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuation (up to approximately Week 22 or throughout the duration of the study)
Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuation (up to approximately Week 22 or throughout the duration of the study)
次要结局
- − Percentage of subjects with juvenile idiopathic arthritis (JIA) American College of Rheumatology (ACR) 30 response at Week 12 and Week 18 − Percentage of subjects with JIA ACR inactive disease at Week 12 and Week 18 − Change from baseline in Juvenile Arthritis Disease Activity Score (JADAS)-27 erythrocyte sedimentation rate (ESR) and JADAS-27 C-reactive protein (CRP) at Week 12 and Week 18
- Incidence of uveitis at various timepoints (including occurrence, type, and severity)
- PK parameters of filgotinib and its primary metabolite GS-829845 (including maximum observed plasma concentration at steady-state [Cmax,ss], area under the plasma concentration-time curve over the dosing interval at steady-state [AUC0-24,ss], and area under the plasma concentration-time curve over the dosing interval at steady-state for the effective exposure [AUCeff,ss])
- Acceptability of the age-appropriate pediatric formulation and the adult commercially developed film-coated tablet formulation assessed by Pediatric Oral Medicine Acceptability Questionnaire for Patients (POMAQ-P)
研究者
Medical Information
Scientific
Alfasigma S.p.A.
研究点 (52)
Loading locations...
相似试验
招募中
3 期
A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid ArthritisRheumatoid arthritis2024-513919-27-00Alfasigma S.p.A.254
招募中
3 期
Open-label extension study with filgotinib in children with juvenile idiopathic arthritis.Juvenile idiopathic arthritis2025-523239-21-00Alfasigma S.p.A.18
招募中
3 期
A study evaluating the effects of filgotinib in children and teenagers with ulcerative colitisUlcerative colitis2024-511458-32-00Alfasigma S.p.A.68
招募中
3 期
A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis2022-501354-10-01Alfasigma S.p.A.487
招募中
2 期
A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Intermediate to High Risk MyelofibrosisMFNCT07443306Chengdu Zenitar Biomedical Technology Co., Ltd64